| Literature DB >> 12493538 |
Dale O Kiesewetter1, Elaine M Jagoda, Chih-Hao K Kao, Ying Ma, Laura Ravasi, Kazuaki Shimoji, Lawrence P Szajek, William C Eckelman.
Abstract
Paclitaxel (Taxol) is a clinically important chemotherapeutic agent. We describe the synthesis of fluoro-, bromo-, and iodopaclitaxel and their [(18)F]fluoro-, [(76)Br]bromo-, and [(124)I]iodo- analogues. [(18)F]Fluoropaclitaxel shows high uptake and rapid clearance from tissues in rats. Preadministration of paclitaxel in normal rats significantly increases (p < 0.005) retention of [(18)F]fluoropaclitaxel and [(76)Br]bromopaclitaxel in blood (33.0%), heart (32.0%), lung (37.6%) kidney (142.4%); and blood (33.4%), lung (42.3%), kidney (62.4%), respectively. [(18)F]Fluoropaclitaxel uptake in the brain of mdr1a/1b(-/-) mice is increased 1400% (p < 1.3e-07) relative to wild-type controls. Preadministration of paclitaxel or XR9576, a modulator, had little effect on the biodistribution in these mdr1a/1b(-/-) mice. As a result, [(18)F]fluoropaclitaxel will be a useful radiopharmaceutical for the study of multidrug resistant tumors.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12493538 DOI: 10.1016/s0969-8051(02)00351-7
Source DB: PubMed Journal: Nucl Med Biol ISSN: 0969-8051 Impact factor: 2.408